Explaining that the COVID story is still not done, and there needs to be advanced preparations to be able to meet those exigencies, Mahima Datla, Managing Director, Biological E Ltd informed that they ...

NEW DELHI (Reuters) - India's Biological E. Ltd will soon start Phase III trials of its COVID-19 vaccine and plans producing 75 million to 80 million doses a month from August, its managing director ...

Biological e ltd managing director Mahima Datla tells Swati Bharadwaj how her company plans to make corbevax a part of the global Covid-19 vaccination programme Biological E's managing director Mahima ...

The company supplied 100 million doses of Corbevax to the central government which were then utilized in pan-India immunization campaigns, mainly in children aged 12-14 years, the release said. Datla ...

Corbevax was launched today for 12-to 14-year-olds in the country. Mahima Datla, the MD of Biological E -- whose vaccine Corbevax was launched today for 12-to 14-year-olds in the country -- today ...

Mahima Datla, managing director of Biological E Limited from Hyderabad and B P Acharya, patron of Federation of Asian Biotech Association (FABA) have been conferred with Dr B S Bajaj Memorial FABA ...

The homegrown Covid-19 vaccine, Corbevax, manufactured by Hyderabad-based Biological E, has been allowed by the Union government to be used as a heterologous booster on Indian population. The company ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...